Agenda Walk-through with Trish

We know a PDF can't tell you everything about how our partnering meetings work. That's why we want Trish to personally walk you through the agenda. You'll see how our unique blend of targeted pharma matchmaking, carefully designed networking, and an enhanced partnering platform can truly set you apart from your competitors. Just give us 3 minutes, and we'll show you exactly what this meeting can do for you.

LOOKING TO INVEST, ACQUIRE, LICENCE OR PARTNER ACROSS IMMUNE CELL ENGAGERS?

Previously limited to blood cancers, immune cell engagers, are now showing compelling results in solid tumors and autoimmune diseases. This expansion highlights their superior tunability over other modalities, like ADCs, with growing interest from biotech, pharma, and investors that are spurring a surge in engager deals across oncology and immunology.

WHY BIOTECH PARTNER?

Capitalizing on growing pharma interest in engagers as a validated drug modality, to engage at the right time as landmark deals (including Sanofi’s $1.9B deal with Dren Bio or AbbVie’s $2.1B deal with Xilio Therapeutics) signal rising momentum in the space

Securing strategic investment and partnerships to initiate competitive development programs, advance biotech pipelines, and ensure long-term revenue sustainability in a tough funding environment

WHY PHARMA & INVESTORS PARTNER?

Maximizing pipeline breadth, patient and commercial market opportunity for best-in-class engagers in blood cancers, as well as accelerating speed-to-market to achieve first-in-class potential in solid tumors and autoimmunity

Capitalizing on breakthrough engager technologies, novel targets, and innovative mechanisms to combine targets with stronger preclinical and clinical validation, facilitating strategic bets, securing long-term growth and pipeline diversification

Tapping into market opportunity for de-risked targets across both oncology and immunology enabling pharma and investors to outpace competitors, realize routes to capital and increase capital efficiency through risk-adjusted ROI

Partnering & Investment Summits by Hanson Wade in Numbers*

70+

attending companies across modalities so pharma could decide which horse to back in a quickly evolving space

5

big pharma companies across business development, search and evaluation, oncology and immunology research provide a comprehensive opportunity to meet the teams assessing due diligence and asset synergy

1-2-1

meetings bookable via the partnering portal for efficient and high yielding conversations between decision-makers

100%

alignment on interests and intentions, increasing the surface area for synergy in research and collaboration goals

*Based on average statistics across Partnering & Investment Summits by Hanson Wade in 2024 and 2025

Testimonials

"It was extremely valuable to be able to easily connect with immunology specific partnering contacts."

Seismic Therapeutics

"The curated attendee list was very novel for this type of conference - just the right people for interaction and decision-making."

Artiva Therapeutics

"The conference panellists were very engaging, and the platform made it easy to schedule 1-to-1 meetings."

Deerfield Management

"Last year's inaugural summit stimulated great scientific debate and was an intimate forum for partnering discussions. This year I'm excited for conversations around different novel approaches to B-cell depletion in autoimmune disease."

Artiva Biotherapeutics

*Based on 2024’s Autoimmunity  Partnering event

REGISTER INTEREST
To the top